Clinical trials: Escitalopram
Depressive Disorder
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients…
- Trial name
- NCT00415142
- Testing
- saredutant (SR48968), escitalopram
- Where
- 8 sites in United States, Croatia and 6 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Insomnia
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
- Trial name
- NCT00296179
- Testing
- zolpidem tartrate
- Volunteers
- 372 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Escitalopram in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the…
- Trial name
- NCT00902564
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis C Infection
Study of Drug Combination on Pharmacokinetics in Healthy Volunteers
The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.
- Trial name
- NCT02175602
- Testing
- Escitalopram, Sertraline, DCV 3DAA FDC
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
International Study to Predict Optimised Treatment - in Depression
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine…
- Trial name
- iSPOT-D (NCT00693849)
- Testing
- Escitalopram, Sertraline, Venlafaxine-XR
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 2,688 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Major Depressive Disorder
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
The purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (MDD [marked depression appearing in the involution period and characterized by…
- Trial name
- NCT01814085
- Testing
- Escitalopram
- Where
- 6 sites in China
- Volunteers
- 225 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Healthy
Bioequivalence Study Comparing Two Formulations of Escitalopram
This is a bioequivalence study, which is a regulatory requirement to ensure comparable in vivo performance, i.e. similarities in terms of safety and efficacy, after administration of two different dosage forms of escitalopram.
- Trial name
- NCT01395433
- Testing
- Escitalopram
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Insomnia, Generalized Anxiety Disorder
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder.
- Trial name
- NCT00235508
- Testing
- Eszopiclone (Lunesta)
- Where
- 64 sites in United States
- Volunteers
- 420 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Study of Escitalopram in Adult Patients With Major Depressive Disorder
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.
- Trial name
- NCT00108979
- Testing
- Escitalopram
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- Forest Laboratories
Healthy
Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
This is a bioequivalence study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited under fasting conditions.
- Trial name
- NCT01149967
- Testing
- Citalopram Hydrobromide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
- Trial name
- NCT01254305
- Testing
- Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Where
- 20 sites in United States
- Volunteers
- 262 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Insomnia, Central Nervous System
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
Primary Objective： 1) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and…
- Trial name
- NCT06680531
- Testing
- YZJ-1139 tablets, Escitalopram oxalate tablets, YZJ-1139 simulated tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
The purpose of this study is to assess the safety and tolerability of Seltorexant as adjunctive therapy to an antidepressant in adolescents with major depressive disorder (MDD) in the short-term compared with placebo.
- Trial name
- NCT04951609
- Testing
- Seltorexant
- Where
- 23 sites in United States, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive…
- Trial name
- NCT00807248
- Testing
- Escitalopram 20 mg, Gaboxadol 5 mg, Gaboxadol 10 mg
- Where
- 22 sites in Austria, Russia
- Volunteers
- 490 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.